Neuropraxis Muenchen-Sued

At Neuropraxis Muenchen-Sued in Unterhaching, Germany, the clinical trial portfolio is centered on nervous system diseases, with studies focused on multiple sclerosis and migraine. The research is aimed at evaluating new treatments, checking safety and tolerability, and understanding how therapies may reduce disease activity or improve symptom control.

• Relapsing forms of multiple sclerosis, including relapsing-remitting and secondary progressive disease
• Migraine and chronic or episodic migraine, with trials addressing both prevention and acute treatment
• Early symptomatic Alzheimer’s disease, with a focus on slowing clinical progression and supporting better disease management

The site’s research includes studies of brain inflammation, disability progression, and clinical effectiveness, reflecting a strong emphasis on therapies that may help people living with chronic neurological conditions.

Several trials at this site are dedicated to multiple sclerosis, especially relapsing forms of MS and secondary progressive multiple sclerosis. These studies are designed to assess whether new or comparative therapies can better control disease activity, reduce inflammation, and delay worsening of disability.

• Testing treatments for relapsing-remitting multiple sclerosis and broader relapsing disease types
• Evaluating approaches for secondary progressive multiple sclerosis with the goal of slowing progression
• Comparing treatment effects on central nervous system inflammation and overall clinical outcomes

This area of research combines safety assessment with measurements of how well therapies may protect the nervous system and support long-term disease control.

The site also conducts important research in migraine, including chronic migraine and episodic migraine. These trials are focused on both prevention and acute relief, aiming to improve treatment options for people who experience frequent or severe headache attacks.

• Preventive treatment research for chronic and episodic migraine
• Studies of therapies intended for the acute treatment of migraine attacks
• Assessing safety, tolerability, and how consistently a treatment may help across attacks

Overall, this work seeks to expand options for symptom control and to better understand how migraine therapies perform in everyday clinical use.

Another key focus at Neuropraxis Muenchen-Sued is early symptomatic Alzheimer’s disease, including people with mild cognitive impairment and mild dementia due to Alzheimer’s disease. The trials in this area are intended to evaluate whether new therapies can influence clinical progression and support better outcomes in the earliest stages of the illness.

• Research in mild cognitive impairment and early Alzheimer’s disease
• Evaluating whether treatment may slow changes in cognitive and functional decline
• Studying safety and potential benefit in people with early-stage disease

This line of research reflects a broader effort to improve care for neurodegenerative disease by identifying treatments that may help preserve daily function for longer.